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Abstract
Background: Experimental autoimmune uveoretinitis (EAU) serves as a model for human intraocular inflammation. IFN-b
has been used in the treatment of certain autoimmune diseases. Earlier studies showed that it ameliorated EAU; however,
the mechanisms involved in this inhibition are still largely unknown.
Methodology/Principal Findings: B10RIII mice were immunized with interphotoreceptor retinoid-binding protein (IRBP)
peptide 161–180 in Complete Freund’s adjuvant. Splenocytes from different time points after immunization were used to
evaluate the expression of IFN-b. An increased expression of IFN-b was observed during EAU and its highest expression was
observed on day 16, 3 days after the peak of intraocular inflammation. Splenocytes and draining lymph node cells from mice
immunized with IRBP161-180 on day 13 and control mice were activated with anti-CD3/anti-CD28 antibodies or IRBP161-180 to
evaluate the production of IFN-c and IL-17. The results showed that IFN-c and IL-17 were significantly higher in immunized
mice as compared to the control mice when exposed to anti-CD3/anti-CD28 antibodies. However, the production of IFN-c
and IL-17 was detected only in immunized mice, but not in the control mice when stimulated with IRBP161-180. Multiple
subcutaneous injections of IFN-b significantly inhibited EAU activity in association with a down-regulated expression of
IFN-c, IL-17 and an enhanced IL-10 production. In an in vitro system using cells from mice, IFN-b suppressed IFN-c
production by CD4
+CD62L
2 T cells, IL-17 production by CD4
+CD62L
+/- T cells and proliferation of CD4
+CD62L
+/- T cells. IFN-b
inhibited the secretion of IL-6, but promoted the secretion of IL-10 by monocytes. IFN-b-treated monocytes inhibited IL-17
secretion by CD4
+CD62L
+/- T cells, but did not influence IFN-c expression and T cell proliferation.
Conclusions/Significance: IFN-b may exert its inhibitory effect on EAU by inhibiting Th1, Th17 cells and modulating relevant
cytokines. IFN-b may provide a potential treatment for diseases mediated by Th1 and Th17 cells.
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Introduction
Interferon (IFN)-b, belongs to the type I interferons, and is
secreted by fibroblasts, monocytes-macrophages and dendritic
cells (DC) during the innate immune response against viral
pathogens [1]. It has been shown to be effective in the treatment of
relapsing-remitting multiple sclerosis [2–3] and various studies
have revealed that it could inhibit inflammation through
regulating T helper (Th) 1 and Th2 cytokines [4–6]. Additional
evidence indicates that IFN-b promotes the production of
interleukin (IL)-10 and inhibits pro-inflammatory cytokines [7–9].
Naive CD4
+ T cells differentiate into distinct subsets after
activation by professional antigen-presenting cells (APC). Tradi-
tionally, CD4
+ effector T cells have been classified into two
subsets: Th1 and Th2 lineages [10]. Th1 cells are induced by
IL-12 and produce large amounts of IFN-c, whereas Th2 cells
predominantly secrete IL-4, IL-5 and IL-13. Th1 cells orchestrate
cellular immunity and Th2 cells regulate humoral immunity and
allergic responses. Recently, Th17 cells have been added to these
lineages and have now been well characterized both in humans
and animals. Th17 cells have been shown to be involved in the
pathogenesis of various clinical autoimmune diseases as well as
their experimental counterparts in animals [11–14]. It has been
shown that the differentiation of naı ¨ve T cells into Th17 cells is
dependent on transforming growth factor (TGF)-b and IL-6,
whereas the maintenance and expansion of Th17 cells is sustained
by IL-23 [12,15–17].
Experimental autoimmune uveoretinitis (EAU) is an organ
specific autoimmune disease. It has been induced in a variety of
animals such as rat and mouse by immunization with a number
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19870of antigens including interphotoreceptor retinoid-binding protein
(IRBP), the soluble retinal antigen [18] or peptides derived from
these autoantigens. Clinical and histopathological studies have
shown a high similarity between this model and human uveitis.
Therefore, this model has been widely used as a counterpart for
human intraocular inflammation [19]. Early studies have shown
that EAU was mainly mediated by Th1 cells. Th2 cells may
provide a protection against this model. Recent studies have
shown that a new Th subset that produces IL-17 (Th17) is also
involved in the development of EAU [20–21]. As mentioned
above, the inhibitory role of IFN-b has been reported in MS
patients and in animal models of autoimmune encephalomyelitis
[2,22–24]. IFN-a, which also belongs to the type I interferons,
has been used in Europe to treat various forms of uveitis [25–27]
and EAU [28–29]. Earlier studies from Japan have shown that
oral IFN-b could ameliorate EAU in rats and evidence was
obtained that this was mediated via NK or NKT cells [30].
Whether IFN-b may exert its effect by interfering with Th1 and/
or Th17 lineages was not addressed yet and was therefore the
subject of the study presented here. Our in vivo experiments
revealed that IFN-b could significantly ameliorate the severity of
EAU in association with an inhibition of Th1, Th17 cells and an
enhanced expression of IL-10. In vitro experiments showed that it
inhibited the production of pro-inflammatory cytokines including
IFN-c, IL-17 and IL-6, but promoted the production of IL-10. It
also suppressed the proliferation of naı ¨ve T cells and effector/
memory T cells. Additionally, IFN-b-treated monocytes were
able to inhibit the production of IL-17 by naı ¨ve T cells and
effector/memory T cells.
Results
Induction of EAU and the dynamic expression of IFN-b in
this model
EAU was successfully induced in B10RIII mice and was
characterized clinically by aqueous flare, cells, and exudates in the
anterior chamber. Histological examination showed a severe
inflammation in the anterior segment as well as in the posterior
segment as evidenced by a massive influx of mononuclear and
polymorphonuclear cells into the retina and choroid, granuloma
formation, vasculitis, photoreceptor loss and vitritis (Figure 1A, B).
This inflammation became evident on day 8 or 9 and reached its
peak on day 13, followed by a rapid regression (Figure 1C). No
intraocular inflammation was observed in the control mice.
Splenocytes and lymph node cells from normal mice and
those at different time points following immunization with
IRBP161-180 were stimulated with LPS and the supernatants
were assessed for IFN-b expression. Lymph node cells did not
express IFN-b,w h e r e a sI F N - b expression in splenocytes was
significantly higher on day 13 and reached its peak on day 16,
followed by a gradual decrease and returning to normal levels
on day 35 (Figure 1D).
Figure 1. Induction of EAU and analysis of the expression of IFN-b in this model. EAU was induced in B10RIII mice by immunization with
50 mg IRBP161-180 in CFA. (A) Inflammatory infiltration in the anterior segment of the eye (after mydriasis). (B) Damaged retinal structure in a B10RIII
mouse after immunization with IRBP161-180. Eyes were obtained 13 days after immunization and stained with haematoxylin/eosin. (C) Mean histology
score during the development of EAU. (D) Splenocytes from normal mice (day 0) and those obtained at different time points after the induction of
EAU were stimulated by LPS for 24 hours. Supernatants were measured for the production of IFN-b by ELISA. Data are representative of three
independent experiments. **p,0.01, *p,0.05, NS=not significant.
doi:10.1371/journal.pone.0019870.g001
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node (DLN) cells were detected by enzyme-linked immunosorbent
assay (ELISA) on day 13 after immunization. The results showed
that IFN-c and IL-17 in the supernatants of splenocytes and DLN
cells stimulated with anti-CD3 and anti-CD28 antibodies from the
immunized mice were significantly higher than those from the
control mice. The production of IFN-c and IL-17 was detected in
the immunized mice, but not in the control mice when stimulated
with IRBP161-180. However, their production was significantly
lower in the experiment with IRBP161-180 stimulation than that
with anti-CD3 and anti-CD28 antibodies stimulation (Figure 2).
In vivo influence of IFN-b on EAU activity, production of
cytokines and T cell proliferation
IFN-b was administered to mice before and after immunization
with IRBP161-180 to examine its influence on EAU activity and
various other parameters. Clinical examination showed that IFN-b
significantly inhibited EAU activity on day 13 (Fig. 3A). However,
it did not influence the incidence or duration of EAU.
Histopathological examination on day 13 or 16 following
immunization revealed that the EAU score in IFN-b-treated mice
was significantly lower than that found in control mice (Figure 3B,
C).
As the highest expression of IFN-b was observed in the
splenocytes on day 16, the splenocytes and DLN cells obtained
from this time point were used to evaluate the influence of IFN-b
on the production of several cytokines and T cell proliferation.
The results showed that the production of IFN-c and IL-17 by
splenocytes or DLN cells was significantly decreased in IFN-b-
treated mice as compared with the control mice. However, the
levels of IL-10 in the supernatants of splenocytes and DLN cells
were significantly higher in IFN-b-treated mice as compared with
controls (Figure 3D–I). IFN-b did not influence the T cell
proliferation in the spleen or in the DLN (data not shown).
In vitro effect of IFN-b on cytokine production by Th1,
Th17 and monocytes and T cell proliferation
An experiment was designed to examine whether IFN-b could
directly inhibit the polarization of Th1 and Th17 cells.
CD4
+CD62L
+ (naı ¨ve) T cells from normal mice stimulated with
IL-12 were cultured with or without IFN-b to evaluate its
influence on the production of IFN-c. The results showed that it
did not affect the production of IFN-c (Figure 4A). CD4
+CD62L
+
T cells stimulated with TGF-b1, IL-6 and IL-23 were cultured
with or without IFN-b to evaluate its effect on the production of
IFN-c and IL-17. The result showed that it significantly inhibited
the production of IL-17 (Figure 4B), whereas it promoted the IFN-
c secretion by these T cells (Figure 4C). An additional experiment
using anti-IFN-c antibody was used to examine whether the
inhibition of IFN-b on IL-17 was mediated by the up-regulated
Figure 2. The expression of IFN-c and IL-17 in EAU mice and control mice. Splenocytes (A and B) and DLN cells (C and D), obtained from
EAU mice or control mice on day 13, were activated with IRBP161-180 (20 mg/ml) or anti-CD3 and anti-CD28 (1 mg/ml) for 72 hours. IFN-c and IL-17
were analyzed by ELISA. Data are representative of three independent experiments. **p,0.01, ND= not detected.
doi:10.1371/journal.pone.0019870.g002
Role of IFN-b in EAU
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19870IFN-c. The result showed that neutralization by anti-IFN-c
antibody resulted in a significantly increased IL-17 expression
under Th17 polarization conditions (Figure 4D), suggesting that it
could partially reverse the inhibition of IFN-b on IL-17
production.
CD4
+CD62L
2 T cells (effector/memory) from normal mice
were cultured with anti-CD3 and anti-CD28 antibodies in the
presence or absence of IFN-b to examine its influence on the
production of cytokines by these cells. The results showed that
IFN-b significantly inhibited the production of both IFN-c and
IL-17 (Figure 5).
The aforementioned experiment revealed a direct inhibition of
IFN-b on the production of IFN-c and IL-17. As the receptor of
IFN-b is also expressed by monocytes [31], a further study was
performed to test whether IFN-b could also exert its effects on
IFN-c and IL-17 production through monocytes. The results
showed that IFN-b-treated monocytes significantly inhibited the
production of IL-17 by both CD4
+CD62L
+ T cells and
CD4
+CD62L
2 T cells (Figure 6A, B). Furthermore, the inhibition
of IFN-b-treated monocytes on CD4
+CD62L
2 T cells was
dependent on IFN-b in a dose dependent manner. However,
IFN-b-treated monocytes did not have any effect on IFN-c
secretion (Figure 6C, D).
Monocytes from the mice immunized with IRBP161-180 on
day 13 were cultured with or without IFN-b to evaluate its
influence on the production of IL-6 and TGF-b,w h i c ha r e
critical for the polarization of Th17 cells, and IL-23, which
sustains the maintenance and expansion of Th17 cells. The
results showed that it significantly inhibited the IL-6 production
b yt h e s ec e l l s( F i g u r e7 A ) .H o w e v e r ,i td i dn o th a v ead e t e c t a b l e
effect on the secretion of TGF-b and IL-23 by these cells
(Figure 7B, C).
As IL-10 has anti-inflammatory properties and is involved in the
regression of EAU [32], a further study was performed to detect
whether IFN-b could exert its inhibitory role through up-regulating
this cytokine. Our results showed that it significantly induced the
monocytes from the normal mice and those immunized with
IRBP161-180 on day 13 and 16 to abundantly produce IL-10. There
was no difference concerning the ability of IFN-b to promote IL-10
production among the tested three groups (Figure 7D).
Figure 3. The influence of IFN-b treatment on EAU activity, production of IFN- c, IL-17 and IL-10. Clinical scores (A) and histology scores
on day 13(B) and day 16 (C) of IFN-b or PBS treated EAU mice. Splenocytes (D-F) and DLN cells (G-I) from day 16 with or without IFN-b treatment were
activated with IRBP161-180 (20 mg/ml) or anti-CD3 and anti-CD28 (1 mg/ml) for 72 hours. Cytokines were analyzed by ELISA. Data are representative of
three independent experiments with at least five mice per group. **p,0.01, *p,0.05.
doi:10.1371/journal.pone.0019870.g003
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b could directly inhibit the proliferation of CD4
+CD62L
+ T cells
and CD4
+CD62L
2 T cells from normal mice. T cell proliferation
was induced with anti-CD3 (1 mg/ml) and anti-CD28 (1 mg/ml)
antibodies in the presence or absence of IFN-b and was then
determined using a non radioactive colorimetric assay. IFN-b
significantly inhibited the proliferation of both T cell subsets
(Figure 8A,B).Afurtherstudywasperformedtoinvestigatewhether
IFN-b could also exert its inhibitory effect on T cell proliferation
through monocytes. CD4
+CD62L
+ T cells and CD4
+CD62L
2 T
cells were cultured with or without IFN-b-treated monocytes and
proliferation was measured as described above. IFN-b-treatment of
monocytes did not influence the proliferation of CD4
+CD62L
+ T
cells or CD4
+CD62L
2 T cells (Figure 8C, D).
Discussion
In this study, we investigated the regulatory effect of IFN-b on
EAU induced by immunization with IRBP161-180 and possible
mechanisms involved in this process. We found an increased
Figure 4. Effect of IFN-b on Th1 and Th17 differentiation. Naı ¨ve T cells cultured with or without IFN-b in Th1-polarizing conditions (10 ng/ml
IL-12) (A) , Th17-polarizing conditions (20 ng/ml IL-6, 5 ng/ml TGF-b1 and 10 ng/ml IL-23) (B-C) or (20 ng/ml IL-6, 5 ng/ml TGF-b1 and 10 ng/ml IL-23
with or without 2 mg/ml anti-IFN-c) (D) for 96 hours. IFN-c and IL-17 were analyzed by ELISA. Data are representative of three independent
experiments. **p,0.01, *p,0.05, NS=not significant.
doi:10.1371/journal.pone.0019870.g004
Figure 5. Effect of IFN-b on the expression of IFN-c and IL-17 by effector/memory T cells. Effector/memory T cells were cultured with or
without IFN-b for 72 hours. Cytokines were detected by ELISA. Data are representative of three independent experiments. *p,0.05.
doi:10.1371/journal.pone.0019870.g005
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and IL-17 upon stimulation either with anti-CD3 and anti-CD28
antibodies or with IRBP161-180 during the active phase of in-
flammation. In vivo experiments showed that IFN-b significantly
attenuated the EAU activity in association with a marked down-
regulation of IFN-c and IL-17. On the other hand, IFN-b
treatment of mice undergoing EAU resulted in an almost three
fold up-regulation of IL-10 production.
The anti-inflammatory and beneficial effect of type I interferons
such as IFN-a and IFN-b in autoimmune diseases such as multiple
sclerosis and uveitis [2,3,25–27] contrasts with a pro-inflammatory
role for IFN-a in systemic lupus erythematosus and dermatomy-
ositis [33-34]. Why type I interferons can act as pathogenic
mediators in some diseases and on the other hand offer possibilities
as a therapeutic agent in others is not clear yet.
Previous studies showed that IFN-a suppressed EAU by down-
regulating TNF-a production [28] and reducing ocular CD45
+ T
cells infiltration [29]. Only few studies have addressed the effect of
IFN-b on EAU and mainly concentrated on T cell proliferation
and IFN-c production [30]. We extended these studies and firstly
examined whether and how IFN-b was expressed during this
model. The highest expression of IFN-b was observed 3 days after
the peak of inflammation which suggests that it may be involved in
the resolution of EAU. IFN-b was mainly produced by splenocytes
and not by draining lymph node cells which confirms earlier
findings [35]. Further in vitro experiments showed that IFN-b
significantly inhibited T cell proliferation as well as the production
of IFN-c, IL-17 and IL-6, whereas it markedly enhanced the
production of IL-10. Collectively, these results suggest that IFN-b
is able to inhibit EAU activity and that this inhibition is possibly
mediated through modulating Th1, Th17 cells and IL-10
production. The second aim of our study was to investigate
whether injection of IFN-b could influence the clinical activity of
EAU as well as other relevant parameters. Our result showed that
multiple injections of this protein before and after immunization
with IRBP peptides could significantly ameliorate the EAU activity
although it did not completely prevent the development of this
disease. We did not investigate IFN-b administration at the time of
disease onset since the model we used is characterized by a rapid
self limiting regression of the disease and an eventual effect of IFN-
b would probably not be detected. Further investigations
concerning other time and dosage schemes are necessary to
delineate the optimal conditions for the IFN-b effect on EAU.
IFN-b significantly inhibited the production of IFN-c and IL-17
upon nonspecific stimulation or specific antigen stimulation. On
the other hand, it promoted the secretion of IL-10. Our data on
IFN-c production are in agreement with earlier studies by Suzuki
et al. in the EAU model in rats [30]. These results are also
consistent with those reported in the treatment of MS patients with
IFN-b [2,7,36]. However, unexpectedly, we failed to find any
influence of in vivo IFN-b treatment on T cell proliferation assays
in vitro. This result is in disagreement with the data published by
Figure 6. Effect of IFN-b-treated monocytes on the expression of IFN-c and IL-17. Naı ¨ve T cells (A and B) and effector/memory T cells (C and
D) were cultured with IFN-b-treated monocytes at a ratio of 5:1 for 72 hours. Cytokines were detected by ELISA. Data are representative of three
independent experiments. *p,0.05, NS=not significant.
doi:10.1371/journal.pone.0019870.g006
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Hedegaard et al. [36]. In the latter study, IFN-b treatment of MS
patients was not associated with an effect of this protein on T cell
proliferation.
The third aim of our study was to examine how IFN-b exerted
its inhibitory role using a number of in vitro experiments. The
studies of the effects of IFN-b on the cytokine production of Th1
and Th17 cells showed that it significantly inhibited both cytokine
production and polarization of Th17 cells, but only suppressed the
cytokine production of Th1 cells. These results are generally in line
with those reported by Axtell et al. [37]. They cultured APC with
naı ¨ve T cells or effector/memory T cells in the presence of TGF-b
and IL-6 and found that IFN-b significantly inhibited IL-17
production by both populations. We disclosed a significant
inhibition of IFN-b on the production of IFN-c by effector/
memory T cells. Our results with regard to the effect of IFN-b on
IFN-c secretion by naı ¨ve T cells are consistent with those reported
by Axtell et al. [37]. They did not find an effect of IFN-b by CD4
+
T cells when these T cells were cultured with APC in the presence
of IL-12. However, McRae et al. [38] found that IFN-b sig-
nificantly inhibited the production of IFN-c by naı ¨ve T cells when
cultured with human DC. This discrepancy with regard to the
IFN-b effect on IFN-c between human and mice is not fully
understood. The origin of IFN-b used in the experiments might be
another reason to explain the observed difference.
Previous studies had shown that enhancing the Th2 response
would be beneficial in clinical treatment of uveitis by preventing
IFN-c production [39]. IFN-b was able to boost the Th2 response
in MS patients [6]. Whether IFN-b inhibits IFN-c partially
through enhancing Th2 responses is a matter of future studies.
IL-12 and IL-18, secreted by monocytes, are critical for Th1
proliferation and IFN-c production by differentiated Th1 cells
[40]. Our results showed that IFN-b did not influence IFN-c
production through monocytes in vitro. Whether IFN-b inhibits
IFN-c in vivo by down-regulating IL-12 and IL-18 production
needs further clarification.
The aforementioned results indicated a direct inhibitory effect
of IFN-b on the production of IL-17. Our further study showed
that its inhibition on IL-17 could be mediated by indirect
mechanisms. The experiment using anti-IFN-c antibody revealed
that the inhibitory role of IFN-b could also be mediated through
enhancing the production of IFN-c. The experiment using IFN-b-
treated monocytes disclosed that IFN-b exerted its effect on IL-17
production through inhibiting IL-6 production by monocytes. It
has been shown that IFN-b may also exert its effect on Th17 cells
through modulating expression of IL-1b, IL-23 and IL-27 in both
humans and mice [23,41-42]. Further study is needed to clarify
whether IFN-b could inhibit Th17 cells through these cytokines
and whether it mediates its inhibitory effect on EAU via this
pathway. It is also worthwhile to point out that we failed to find a
detectable effect of IFN-b on the production of TGF-b,a n
important cytokine for Th17 polarization, and IL-23 by
monocytes, a critical cytokine for survival of Th17 cells. Taken
together, these results suggest that IFN-b not only inhibited the IL-
17 production by direct or indirect routes, but also prevented
Th17 polarization through modulating IL-6 secretion.
Our study also investigated the effects of IFN-b on IL-10 and T
cell proliferation, which are all important factors in the immune
response or in inflammation. The results showed that IFN-b
significantly promoted the production of IL-10 by monocytes upon
Figure 7. Effect of IFN-b on IL-6, TGF-b, IL-23 and IL-10 production by monocytes. Monocytes from immunized mice on day 13 (or on day 0
and day 16 where indicated), cultured with or without IFN-b (250 U/ml) for 24 hours, were stimulated with LPS (100 ng/ml) for another 24 hours.
Cytokines were detected by ELISA. Data are representative of three independent experiments. **p,0.01, NS=not significant.
doi:10.1371/journal.pone.0019870.g007
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with that reported by Chang et al. [43] They found that the effect
of LPS stimulation on the production of IL-10 was principally
mediated by IFN-b. The T cell proliferation experiment showed
that IFN-b could significantly inhibit the proliferation of these
cells, which is contrary to our in vivo findings but in agreement
with earlier studies in rats with EAU [30].
In conclusion, our study showed that IFN-b treatment
significantly inhibited the expression of EAU activity. In vivo
and in vitro experiments revealed that this inhibitory effect was
mediated by suppressing both Th1 and Th17 cells and through an
up-regulation of IL-10 expression. These results suggest that IFN-
b provides a potential treatment for diseases mediated by both
Th1 and Th17 cells.
Materials and Methods
Reagents and Mice
Murine IL-12, IL-6, IL-23, anti-IFN-c antibody and human
TGF-b1 were purchased from R&D systems (Minneapolis, Minn,
USA). Murine IFN-b was obtained from PBL (Piscataway, NJ,
USA). Anti-CD3 and anti-CD28 antibodies were purchased from
eBioscience (San Diego, CA, USA). IRBP161-180 (SGIPYII-
SYLHPGNTILHVD) was synthesized by Shanghai Sangon
Biological Engineering Technology & Services Limited Company.
LPS and CFA containing 1.0mg/ml of Mycobacterium tubercu-
losis was obtained from Sigma-Aldrich (St. Louis, MO).
B10RIII mice (6–8 weeks) were purchased from Jackson
Laboratory and were housed under specific pathogen free
conditions. All animals were treated according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
EAU induction and treatment
B10RIII mice (8–12 weeks)wereimmunized subcutaneouslywith
a 200 ml emulsion containing 50 mgI R B P 161-180 in CFA. Control
mice received a subcutaneous injection of an emulsion of 50 mlP B S
and 150 ml CFA. The clinical and histological scoring of EAU was
performed according to criteria described previously [44–45].
Briefly, the severity of EAU was evaluated in a masked fashion of a
scale of 0–4 based on the number, type, and size of lesions.
Murine IFN-b (1000U suspended in 100 ml of PBS) or PBS was
administered subcutaneously to IRBP161-180 immunized mice every
otherdayfromdayonebeforeimmunizationtotheendofthestudy.
The mice were observed daily by slit lamp microscopy and
ophthalmoscopy. On day 16 after immunization, the splenocytes
or DLN cells (2610
6/ml) were stimulated with soluble anti-
CD3 (1 mg/ml) and soluble anti-CD28 (1 mg/ml) or IRBP161-180
(20 mg/ml) for 72 hours to detect the expression of IFN-c, IL-17
and IL-10.
Cell purification
CD4
+CD62L
+ naı ¨ve T cells were isolated from splenic single-cell
suspensions with a CD4
+CD62L
+ T cell isolation kit (Miltenyi
Biotec, Palo Alto, CA). Splenic single-cell suspensions were
incubated with a cocktail of biotin-conjugated antibodies and
anti-biotinmicrobeadsfornegativesortingofCD4
+T cells.CD4
+T
cellswerethenusedtoseparateCD4
+CD62L
+/2 Tcellsbyaddition
Figure 8. Effect of IFN-b on T cell proliferation. Naı ¨ve T cells (A) or effector/memory T cells (B) from normal mice cultured with anti-CD3 (1 mg/
ml) and anti-CD28 (1 mg/ml) in the presence or absence IFN-b for 72 hours. IFN-b-treated monocytes cultured with naı ¨ve T cells (C) or effector/
memory T cells (D) at a ratio of 1:5 for 72 hours. Proliferation was detected by modified MTT. Data are representative of three independent
experiments with at least three mice per group. *p,0.05, NS=not significant.
doi:10.1371/journal.pone.0019870.g008
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manufacturer’s instructions. The purity of isolated CD4
+CD62L
+
naı ¨ve T cells and CD4
+CD62L
2 effector/memory T cells, as
identified by flow cytometry (FCM) analysis, was shown to be both
higher than 95%. In addition, splenic single-cell suspensions were
used to separate monocytes through incubation with the recom-
mended volume of anti-CD11b beads according to the manufac-
turer’s instructions. The purity of isolated CD11b
+ monocytes,
identified by FCM, was more than 95%.
Cell culture
Splenocytes (2610
6/ml), obtained from EAU mice without
IFN-b or PBS injection on days 0, 13, 16, 21, 28 and 35 after
immunization, were stimulated with LPS (100ng/ml) for 72 hours
and the supernatants were collected to evaluate the expression of
IFN-b. On day 13 after immunization, splenocytes (2610
6/ml)
obtained from EAU mice or control mice were stimulated with
soluble anti-CD3 (1 mg/ml) and soluble anti-CD28 (1 mg/ml) or
IRBP161-180 (20 mg/ml) for 72 hours and the supernatants were
collected to examine IFN-c and IL-17 expression.
CD4
+CD62L
+ naı ¨ve T cells at a concentration of 1.5610
6/
ml, cultured in RPMI 1640 (Gibco BRL; Invitrogen) supple-
mented with 2% penicillin/streptomycin and 10% fetal bovine
serum (complete medium) in 96-well plates were stimulated with
soluble anti-CD3 and anti-CD28 (1 mg/ml) for 96 hours in Th1-
polarizing(10ng/ml IL-12) or Th17-polarizing (20ng/ml IL-6,
5ng/ml TGF-b1a n d1 0 n g / m lI L - 2 3w i t ho rw i t h o u t2mg/ml
anti-IFN-c) conditions in the presence or absence of IFN-b
(250U/ml). CD4
+CD62L
2 (effector/memory) T cells at a
concentration of 1.5610
6/ml were cultured for 72 hours in
t h ep r e s e n c eo ra b s e n c eo fI F N - b (250U/ml). Eventually,
supernatants were collected to detect the expression of IFN-c
and IL-17.
Coculture of IFN-b treated monocytes with CD4
+CD62L
+/2
T cells
Monocytes were stimulated with IFN-b (0–1000U/ml) for
24 hours. They were washed and cultured with CD4
+CD62L
+
(naı ¨ve) T cells or CD4
+CD62L
2 (effector/memory) T cells at a
ratio of 1:5 in the presence of soluble anti-CD3 and anti-CD28
(1 mg/ml). Supernatants on day 3 were analyzed for IFN-c and IL-
17. Meanwhile, T cell proliferation was detected. IFN-b-treated
monocytes were stimulated with LPS for another 24 hours and the
supernatants were collected to analyze the levels of IL-6, TGF-b,
IL-23 and IL-10.
Cell proliferation
T cell proliferation was determined using a non radioactive
colorimetric assay. 10 ml WST-8 (2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2, 4-disulfophen-yl)-2H-tetrazolium, monoso-
dium salt) in 200 ml complete culture medium was added and
incubated for 4 hours. The absorbance was determined at 450 nm
using an ELISA reader (BIO-TEK Instruments).
ELISA
Levels of IL-17, IFN-c, IL-6, TGF-b, IL-23, IL-10 and IFN-b
were measured using commercially available ELISA kits according
to the manufacturer’s instructions with detection limits of 15.6 pg/
ml, 31.3 pg/ml, 15.6 pg/ml, 15.6 pg/ml, 31.3 pg/ml, 31.3 pg/ml
and 15.6 pg/ml respectively. The following ELISA kits were
purchased as indicated: IL-17, IFN-c, IL-6, TGF-b and IL-10
(R&D Systems (Minneapolis, Minn, USA)); IL-23 (Bendermed
system (Vienna, Austria, Europe)); IFN-b (PBL company (Piscat-
away, NJ, USA)).
Statistical analysis
Statistical significance was analyzed by the one-way analysis of
variance, Student t test and Mann-Whitney U test. Data were
expressed as the mean 6 standard deviation (SD). A P value below
0.05 was taken as a statistically significant difference.
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